Project Grant R01CA303968
Award Date 8/27/25
Completion Date 7/31/30
Dollars Obligated $663K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Cancer Institute (NCI), part of the National Institutes of Health, awarded a $618,928 Project Grant under CFDA 93.396 (Cancer Biology Research) to the Regents of the University of California, Berkeley (UC Berkeley). The project, titled "Immunosuppressive Mechanisms of Intratumoral Regulatory T Cells," aims to investigate the role of regulatory T cells in suppressing antitumor immune responses within tumors and in tumor-draining lymph nodes. The key objectives are to...
- This federal Project Grant award of $421,685 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to investigate the "reactive" immune system in tumors and the tumor microenvironment. The primary objective is to discover discrete niches within the tumor microenvironment that are conducive to anti-tumor immunity, in order to guide the development of more effective cancer immunotherapies. The research approach combines spatial...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is funding research to develop "TNF-ALPHA-'ARMED' TCR VECTORS TO ENHANCE ADOPTIVE CELL THERAPY FOR SOLID TUMORS". The $647,632 grant, awarded on March 11, 2025, supports the University of California, Los Angeles in exploring the use of T-cell receptors (TCRs) and chimeric antigen receptors (CARs) engineered to secrete higher levels of tumor necrosis factor alpha (TNF-alpha) to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $677,787 to The Regents of the University of California, San Francisco (UCSF) to investigate novel immune mechanisms that allow tumors to evade treatment. The research aims to characterize a population of macrophages that express the AIRE gene and examine their role in suppressing anti-tumor immunity, with the goal of identifying new therapeutic targets to enhance...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding how different forms of cell death, particularly programmed necrosis, can alter the immune response and impact tumor growth. The $568,538 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a 5-year study to investigate the role of the cytokine interleukin-1 alpha in mediating immune suppression and promoting...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $3,182,665.00 in funding to The Washington University in Missouri to conduct research on how natural killer (NK) cells impact the effectiveness of immune checkpoint therapy for treating tumors. The research aims to: 1) elucidate the mechanisms by which NK cells constrain immune checkpoint therapy, 2) evaluate the contribution of the NKG2D receptor, and 3) translate the...
- The federal Project Grant award of $156,080 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) aims to elucidate the functional role of KLRG1-expressing conventional helper T cells in the tumor microenvironment and develop a novel immunotherapy to selectively deplete these cells. The grant recipient, Mayo Clinic Arizona, will investigate the immunosuppressive mechanisms of KLRG1+ T cells and explore their potential as biomarkers for response to immune checkpoint...
- The University of California, Davis (UC Davis) was awarded a $615,399 Project Grant from the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395) to develop a transformable nanoparticle (TNP) platform for on-demand modulation of the tumor microenvironment. The 5-year project aims to leverage the tumor-retaining properties of the TNP platform to selectively deliver therapeutic peptides, small molecules, and proteins that can reprogram the tumor microenvironment and...
- This $156,276 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research at the University of California, Berkeley (UC Berkeley) to investigate tumor antigen presentation by dendritic cells in pancreatic cancer. The key objectives are to compare the tumor immunopeptidomes presented directly by cancer cells versus those cross-presented by dendritic cells, and evaluate how this impacts T cell infiltration in pancreatic tumors. The...
- This $422,799 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore supports research to understand and mitigate the mechanisms of treatment resistance in chimeric antigen receptor (CAR) T cell therapy for blood cancers. The research aims to characterize the process of CAR-mediated trogocytosis, in which target antigens are transferred from tumor cells to CAR T cells, leading to rapid loss of the target antigen...